Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAPK1 | P53355 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | ALKBH1 | Q13686 | 6/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.40 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30496472 | 1.00 | DAPK1 (0.44) | DAPK1SMN1; SMN2RECQLMAPK10ADORA2A | |
| SCHEMBL21883964 | 0.91 | SMN1; SMN2 (0.41) | DAPK1SMN1; SMN2RECQLMAPK10ADORA2A | |
| SCHEMBL30496452 | 0.91 | PDE3B (0.45) | DAPK1SMN1; SMN2RECQLMAPK10ADORA2A | |
| SCHEMBL30496441 | 0.91 | SMN1; SMN2 (0.41) | DAPK1SMN1; SMN2RECQLMAPK10ADORA2A | |
| SCHEMBL21883535 | 0.91 | PDE3B (0.45) | DAPK1SMN1; SMN2RECQLMAPK10ADORA2A | |
| SCHEMBL23322497 | 0.89 | ALKBH1 (0.40) | DAPK1SMN1; SMN2RECQLMAPK10ADORA2A | |
| SCHEMBL30496470 | 0.89 | ALKBH1 (0.40) | DAPK1SMN1; SMN2RECQLMAPK10ADORA2A | |
| SCHEMBL21801294 | 0.87 | RECQL (0.43) | SMN1; SMN2RECQLMAPK10ALKBH1F2RL3 | |
| SCHEMBL30496455 | 0.87 | RECQL (0.43) | SMN1; SMN2RECQLMAPK10ALKBH1F2RL3 | |
| SCHEMBL21883542 | 0.85 | PPARG (0.40) | SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112673008-B | Hypoxanthine compounds | 橘生药品工业株式会社 | 2023-07-18 | — | — | CN | disclosed |
| US-20210214357-A1 | HYPOXANTHINE COMPOUNDS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2021-07-15 | — | — | US | disclosed |
| EP-3819299-A1 | HYPOXANTHINE COMPOUND | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2021-05-12 | — | — | EP | disclosed |
| CN-112673008-A | Hypoxanthine compound | 橘生药品工业株式会社 | 2021-04-16 | — | — | CN | disclosed |
| WO-2020054825-A1 | HYPOXANTHINE COMPOUND | キッセイ薬品工業株式会社 | 2020-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214357-A1 | HYPOXANTHINE COMPOUNDS | HPRT1, DHPS, PAH | DAPK1 4081/4885SMN1; SMN2 3418/4885RECQL 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.